Medical Radioisotopes

Ac-225 is the cornerstone of Targeted Alpha Therapy (TAT).

Its high-energy emissions allow for the pinpoint destruction of cancer cells with minimal impact on healthy tissue, offering new hope for patients with late-stage or resistant cancers.

Tc-99m is used in 80% of nuclear medicine procedures worldwide, and is critical for cardiac, bone, and kidney imaging.

SCMR provides a strategic, reactor-free backup supply to ensure hospitals maintain uninterrupted access to this vital diagnostic tool.

Sc-47 is a next-generation "theranostic" isotope that combines targeted tumor therapy with high-resolution SPECT imaging in a single nuclide.
 

SCMR is evaluating high-power electron accelerator pathways to produce Sc-47, offering a versatile, reactor-free solution for the future of cancer treatment.

Ra-226 is the essential feedstock for Ac-225 production, and the foundation of our supply chain.
 

SCMR’s ability to secure and process Ra-226 ensures a reliable, vertically integrated pipeline for the global alpha therapy market.

Cu-67 offers a unique "dual-action" capability, functioning as both a potent therapeutic agent and a high-resolution imaging tool.

It is ideal for treating Lymphoma and neuroendocrine tumors while providing real-time diagnostic feedback.